SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.26
-1.17 (-2.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close45.43
Open44.52
Bid40.50 x 1300
Ask45.50 x 1100
Day's Range44.12 - 44.67
52 Week Range37.43 - 45.62
Volume2,618,699
Avg. Volume1,031,044
Market Cap110.03B
Beta (3Y Monthly)0.37
PE Ratio (TTM)22.81
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.86 (4.10%)
Ex-Dividend Date2018-05-09
1y Target Est52.00
Trade prices are not sourced from all markets
  • This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment
    Investor's Business Dailyyesterday

    This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment

    Shares of French pharmaceutical giant Sanofi dipped Friday after the FDA rejected its application for a diabetes treatment created under a partnership with Lexicon Pharmaceuticals.

  • Reutersyesterday

    FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

    The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division, and as the French drugmaker faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.

  • Biogen Stock Crashes on Termination of Alzheimer's Studies
    Zacksyesterday

    Biogen Stock Crashes on Termination of Alzheimer's Studies

    Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

  • Emergent Begins Phase III Study on Anthrax Vaccine AV7909
    Zacks3 days ago

    Emergent Begins Phase III Study on Anthrax Vaccine AV7909

    Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

  • Benzinga4 days ago

    Altimmune's Flu Shot Study: What You Need To Know

    The nanocap biotech company said Tuesday that additional data from a Phase 2 extension study of its NasoVAX, an intranasal influenza vaccine candidate, showed that 100 percent of the evaluated subjects remained seroprotected. The Phase 2 extension study enlisted the subjects from the highest dose group of the midstage study to evaluate the duration of immunity one year after vaccination. All eight subjects out of the 15 invited, who returned an average of 13.5 months after vaccination, remained seroprotected.

  • Analysts Are Highly Optimistic on Sanofi in March
    Market Realist4 days ago

    Analysts Are Highly Optimistic on Sanofi in March

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts have set Sanofi’s (SNY) 12-month consensus target price at $52, 15.79% higher than the stock’s

  • Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
    Zacks5 days ago

    Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

    Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

  • Exclusive: Sanofi says working on CEO succession plan
    Reuters5 days ago

    Exclusive: Sanofi says working on CEO succession plan

    Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday. Sanofi has an age limit of 65 for its CEO. Brandicourt will be 65 in February 2021.

  • Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
    Zacks5 days ago

    Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

    Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

  • Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool10 days ago

    Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript

    LXRX earnings call for the period ending December 31, 2018.

  • Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
    Zacks10 days ago

    Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

    Key highlights of the past week are regulatory and pipeline developments.

  • Should Value Investors Consider Sanofi (SNY) Stock Now?
    Zacks10 days ago

    Should Value Investors Consider Sanofi (SNY) Stock Now?

    Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

  • Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
    Zacks11 days ago

    Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

    The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

  • Reuters12 days ago

    Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

    The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.

  • PR Newswire12 days ago

    FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.

  • Reuters12 days ago

    Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

    The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.

  • Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
    Zacks12 days ago

    Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

    Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

  • Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
    Investor's Business Daily15 days ago

    Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

    On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.

  • GlobeNewswire15 days ago

    Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report

      Press Release   Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)   Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 8, 2019 ...

  • GlobeNewswire16 days ago

    Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps

    March 8, 2019 - The  U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with severe CRSwNP often experience recurrence despite previous treatment with surgery and/or systemic corticosteroids.

  • Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
    Zacks17 days ago

    Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA

    The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

  • Top Stock Reports for Salesforce, Booking Holdings & VMware
    Zacks17 days ago

    Top Stock Reports for Salesforce, Booking Holdings & VMware

    Top Stock Reports for Salesforce, Booking Holdings & VMware

  • 3 Big Pharmas Trying to Pop the Rebate Bubble
    Motley Fool17 days ago

    3 Big Pharmas Trying to Pop the Rebate Bubble

    Pharmaceutical companies are suddenly eager to lower drug prices.

  • What Are Mylan’s Key Growth Drivers in Fiscal 2019?
    Market Realist17 days ago

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY